Literature DB >> 10167341

Economic foundations of cost-effectiveness analysis.

A M Garber1, C E Phelps.   

Abstract

To address controversies in the applications of cost-effectiveness analysis, we investigate the principles underlying the technique and discuss the implications for the evaluation of medical interventions. Using a standard von Neumann-Morgenstern utility framework, we show how a cost-effectiveness criterion can be derived to guide resource allocation decisions, and how it varies with age, gender, income level, and risk aversion. Although cost-effectiveness analysis can be a useful and powerful tool for resource allocation decisions, a uniform cost-effectiveness criterion that is applied to a heterogeneous population level is unlikely to yield Pareto-optimal resource allocations.

Mesh:

Year:  1997        PMID: 10167341     DOI: 10.1016/s0167-6296(96)00506-1

Source DB:  PubMed          Journal:  J Health Econ        ISSN: 0167-6296            Impact factor:   3.883


  102 in total

1.  Assessing the cost-effectiveness of pharmacogenomics.

Authors:  D L Veenstra; M K Higashi; K A Phillips
Journal:  AAPS PharmSci       Date:  2000

Review 2.  The (near) equivalence of cost-effectiveness and cost-benefit analyses. Fact or fallacy?

Authors:  C Donaldson
Journal:  Pharmacoeconomics       Date:  1998-04       Impact factor: 4.981

3.  Health technology assessment with risk aversion in health.

Authors:  Darius N Lakdawalla; Charles E Phelps
Journal:  J Health Econ       Date:  2020-06-06       Impact factor: 3.883

4.  Efficient use of health care resources: the interaction between improved health and reduced health related income loss.

Authors:  Michael Hoel
Journal:  Int J Health Care Finance Econ       Date:  2002-11

Review 5.  The role of cost-effectiveness analysis in the era of pharmacogenomics.

Authors:  Christopher R Flowers; David Veenstra
Journal:  Pharmacoeconomics       Date:  2004       Impact factor: 4.981

6.  The cost of an additional disability-free life year for older Americans: 1992-2005.

Authors:  Liming Cai
Journal:  Health Serv Res       Date:  2012-06-07       Impact factor: 3.402

7.  Standardizing the inclusion of indirect medical costs in economic evaluations.

Authors:  Pieter H M van Baal; Albert Wong; Laurentius C J Slobbe; Johan J Polder; Werner B F Brouwer; G Ardine de Wit
Journal:  Pharmacoeconomics       Date:  2011-03       Impact factor: 4.981

8.  Volunteer orthopedic surgical trips in Nicaragua: a cost-effectiveness evaluation.

Authors:  Andrew T Chen; Andrew Pedtke; Jeffrey K Kobs; George S Edwards; R Richard Coughlin; Richard A Gosselin
Journal:  World J Surg       Date:  2012-12       Impact factor: 3.352

9.  Cost effectiveness of treating low HDL-cholesterol in the primary prevention of coronary heart disease.

Authors:  Joel W Hay; Kimberly L Sterling
Journal:  Pharmacoeconomics       Date:  2005       Impact factor: 4.981

10.  Robotic versus laparoscopic distal pancreatectomy: a French prospective single-center experience and cost-effectiveness analysis.

Authors:  Regis Souche; Astrid Herrero; Guillaume Bourel; John Chauvat; Isabelle Pirlet; Françoise Guillon; David Nocca; Frederic Borie; Gregoire Mercier; Jean-Michel Fabre
Journal:  Surg Endosc       Date:  2018-02-02       Impact factor: 4.584

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.